When it comes to kidney cancer, there has been more promising news as of late. Treatments for the disease have changed dramatically over the past few years. We now have new drugs that have shown very significant benefits for our patients whose cancer has unfortunately returned after surgical removal.
Most of these new drugs cut the blood supply to tumors, essentially “starving” them. These type of drugs are called antiangiogenic drugs, or angiogenesis inhibitors.
Deputy Director; Chair of Pharmacology and Therapeutics; Chair of Translational Research
Cancer research is really at the heart of everything we do at Roswell Park. Our mission—to understand, prevent and cure cancer—cannot move forward without it.
Although we focus on research each and every day at Roswell Park, I want to highlight its role this month for National Cancer Research Month and help explain a little about how cancer research works.
Laboratory Administrator, Dept. of Laboratory Medicine, RPCI
Roswell Park patients rarely meet the team working behind the scenes – a team just as dedicated to understanding, preventing and curing cancer.
This past week (April 22-26, 2013) marked National Laboratory Professionals Week. The clinical laboratory team at RPCI is very aware that behind every sample we receive and analyze, there is a patient with a story.
Assistant Professor, Departments of Urology and Immunotherapy
Until recently, radiation therapy has played a very limited role in the treatment of kidney tumors. But, as Kidney Cancer Awareness Month winds down, I want to share with you a promising discovery and new clinical research study that may introduce a new role for radiation in fighting this disease.
Last week's Roswellness Radio went inside Roswell Park's new Center for Personalized Medicine (CPM), a state-of-the-art facility that uses sequencing tools to provide individualized care for cancer patients.
The Gynecologic Oncology Group (GOG) has announced the results of a new study that may change the standard of care for women with advanced or recurrent cervical cancer. The findings of this clinical trial were recently released by the National Cancer Institute (NCI). One of the goals of this GOG study was to evaluate the effectiveness of a new treatment called bevacizumab (brand name AvastinTM). This agent is believed to block the growth of nutrient-supplying blood vessels that form in cancerous tumors.
Although rare, about 38,000 Americans die from pancreatic cancer each year, making it the fourth deadliest type of cancer in the United States. In an effort to slow the death rate of this disease, doctors and researchers have worked feverishly to come up with advancements in treatment.
This week's episode of Roswellness Radio featured Zachary Grossman, MD, FACR, Chair of Diagnostic Radiology & Nuclear Medicine, and Chief Nuclear Medicine Technologist John Warner. The two discussed the role of nuclear medicine in cancer imaging and diagnosis.
Christine Ambrosone, PhD, Chair of the Department of Cancer Prevention and Control, Stephen Edge, MD, FACS, Medical Director of the Breast Center and Chief of Breast Surgery, and Carl Morrison, MD, DVM, Clinical Chief of the Department of Pathology & Laboratory Medicine, joined last Sunday's Roswelless Radio to discuss new research on different types of breast cancer.
